Literature DB >> 12847169

Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome.

R H W M Derksen1, P G de Groot, L J Kappelle.   

Abstract

The authors describe course and outcome of eight patients with ischemic stroke as the first thrombotic manifestation of antiphospholipid syndrome who received low-dose aspirin as prophylactic treatment. During 8.9 years of follow-up, two patients had a recurrent stroke. Recurrent stroke rate per 100 patient-years on aspirin was 3.5 (95% CI 0.4 to 12.5).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12847169     DOI: 10.1212/01.wnl.0000072324.59029.92

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Antiphospholipid antibodies in young adults with stroke.

Authors:  Robin L Brey
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

2.  Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.

Authors:  Tunde Tarr; Gabriella Lakos; Harjit Pal Bhattoa; Pal Soltesz; Yehuda Shoenfeld; Gyula Szegedi; Emese Kiss
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

3.  Cerebrovascular disease associated with antiphospholipid antibodies: more questions than answers.

Authors:  Carolyn Hawkins; Paul Gatenby; Roger Tuck; Gytis Danta; Colin Andrews
Journal:  J Autoimmune Dis       Date:  2006-03-30

4.  Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome.

Authors:  Hirohisa Okuma; Yasuhisa Kitagawa; Takashi Yasuda; Kentaro Tokuoka; Shigeharu Takagi
Journal:  Int J Med Sci       Date:  2009-12-05       Impact factor: 3.738

5.  Controversies in the antiphospholipid syndrome: can we ever stop warfarin?

Authors:  Ana G Fonseca; David P D'Cruz
Journal:  J Autoimmune Dis       Date:  2008-11-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.